Currently Viewing:
The American Journal of Managed Care March 2014
STABLE Results: Warfarin Home Monitoring Achieves Excellent INR Control
Grace DeSantis, PhD; Jackie Hogan-Schlientz, RN, BSN; Gary Liska, BS; Shari Kipp, BS; Ramarion Sallee; Mark Wurster, MD; Kenneth Kupfer, PhD; and Jack Ansell, MD
Do Strict Formularies Replicate Failure for Patients With Schizophrenia?
Dana P. Goldman, PhD; Riad Dirani, PhD; John Fastenau, MPH, RPh; and Ryan M. Conrad, PhD
The Economics of Resistant Pathogens and Antibiotic Innovation
Michael R. McKellar, BA; Michael E. Chernew, PhD; and A. Mark Fendrick, MD
Beyond Black and White: Race/Ethnicity and Health Status Among Older Adults
Judy H. Ng, PhD; Arlene S. Bierman, MD, MS; Marc N. Elliott, PhD; Rachel L. Wilson, MPH; Chengfei Xia, MS; and Sarah Hudson Scholle, DrPH
Currently Reading
Cost-Effectiveness of a Peer and Practice Staff Support Intervention
Christopher S. Hollenbeak, PhD; Mark G. Weiner, MD; and Barbara J. Turner, MD, MSED
Medical Homes and Cost and Utilization Among High-Risk Patients
Susannah Higgins, MS; Ravi Chawla, MBA; Christine Colombo, MBA; Richard Snyder, MD; and Somesh Nigam, PhD
Collaborative DTM Reduces Hospitalization and Healthcare Costs in Patients With Diabetes Treated With Polypharmacy
Lauren Brophy, PharmD, FAHM; Amanda Williams, PharmD; Eric J. Berman, DO, MS; David Keleti, PhD; Karen E. Michael, RN, MSN, MBA; Margaret Shepherd, RPh, FAHM; Scott A. Fox, MS, MEd; Christine Jacobs,
Documentation of the 5 As for Smoking Cessation by PCPs Across Distinct Health Systems
Rebecca J. Williams, DrPh; Andrew L. Masica, MD; Mary Ann McBurnie, PhD; Leif I. Solberg, MD; Steffani R. Bailey, PhD; Brian Hazlehurst, PhD; Stephen E. Kurtz, PhD; Andrew E. Williams, PhD; Jon E. Pur
Assessing the Chiral Switch: Approval and Use of Single-Enantiomer Drugs, 2001 to 2011
Walid F. Gellad, MD, MPH; Phillip Choi, BS; Margaret Mizah, PharmD; Chester B. Good, MD, MPH; and Aaron S. Kesselheim, MD, JD, MPH

Cost-Effectiveness of a Peer and Practice Staff Support Intervention

Christopher S. Hollenbeak, PhD; Mark G. Weiner, MD; and Barbara J. Turner, MD, MSED
A cost-effectiveness analysis of a peer and practice staff support intervention to reduce coronary heart disease risk and blood pressure in African Americans.
Objectives: We examined the cost-effectiveness of an intervention to reduce coronary heart disease (CHD) risk and blood pressure in African Americans.

Study Design: Stochastic cost-effectiveness analysis alongside a clinical trial, augmented by a Markov model of lifetime cost-effectiveness.

Methods: In 2 urban academic primary care practices, we randomized African American patients with uncontrolled hypertension to a 6-month intervention of office practice and peer coach behavioral support (N = 136) or informational brochures about CHD risk factors (N = 144). Costs were estimated from the perspective of the provider. Outcomes included estimated CHD events avoided over 6 months and reduction in systolic blood pressure (SBP) (mm Hg). Subgroup analysis was performed for compliers who received an “effective” dose of the peer coach and office staff visits. Long-term cost-effectiveness was estimated by applying the clinical trial cost and effectiveness into a Markov model of CHD risk.

Results: The average cost for the behavioral support intervention group was $435.36 compared with $74.39 for the brochure control group. The incremental cost-effectiveness ratio (ICER) was $47 per mm Hg reduction in SBP and $453,419 per CHD event avoided in 6 months. Modeled over a 10-year horizon, the intervention had an ICER only as high as $3998 per incremental quality-adjusted life-year.

Conclusions: A community-primary care practice behavioral intervention to reduce hypertension in African Americans with sustained uncontrolled hypertension does not appear to be cost-effective in the first 6 months. If intervention results are sustained over the long term, the program may be cost-effective over the patient’s lifetime.

Am J Manag Care. 2014;20(3):253-260
A community and primary care practice behavioral intervention may be cost-effective to reduce hypertension in African Americans with sustained uncontrolled hypertension. From the payer perspective, the intervention appears to be:
  • Not likely to be cost-effective in reducing coronary heart disease in the first 6 months.

  • Likely to be cost-effective in lowering blood pressure in the first 6 months.

  • Cost-effective in terms of incremental cost per quality-adjusted life-year over the lifetime of the patient if the intervention results are sustained.
Innovative models of primary care offer the potential to reduce disparities in health outcomes for vulnerable populations with chronic diseases.1 Cost-effectiveness studies have reported that future healthcare utilization and costs can be reduced by implementing a diabetes patient registry along with clinical meetings.2 Supplementing a registry with education for patients with diabetes about self-management and improving professional quality of care also meets standard guidelines of increasing quality-adjusted life-years (QALYs).3 However, few cost analyses have been conducted of interventions based on Wagner’s chronic care model that focus on reducing coronary heart disease (CHD) risk and improving blood pressure (BP) in those from racial/ethnic minority backgrounds.

We report a cost-effectiveness analysis of a randomized, controlled trial of a 6-month community- and staff-based intervention of behavioral support and education for African Americans with sustained, uncontrolled hypertension based on a practice-based registry. All subjects received educational brochures and usual physician care while intervention subjects received 3 community support phone calls from trained peers from the same practices alternating with personal counseling by trained mid-level staff at 2 practice visits on alternate months. The study outcomes were 6-month changes in systolic blood pressure (SBP) and CHD risk. These results add to evidence of the potential cost-effectiveness from a provider standpoint of adopting features of the chronic care model to empower patients to reduce CHD risk due to poorly controlled risk factors.


Study Participants

Study subjects were recruited from July 2007 through November 2009 in 2 urban academic general internal medicine practices largely serving low-income patients. Subjects were identified from a registry of all 9135 African American patients aged 40 to 75 years receiving longitudinal care (2+ visits in 2 years). We identified those patients with treated but uncontrolled hypertension per the 7th Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) targets (ie, SBP 130 mm Hg or higher, or diastolic blood pressure [DBP] 80 mm Hg or higher, if chronic kidney disease or diabetes; otherwise, SBP 140 mm Hg or higher, or DBP 90 mm Hg or higher) and at least 1 value 10 mm Hg above goal.4 Of 1057 subjects with uncontrolled hypertension, recent lipid levels, and at least moderate adherence to keeping primary care visits, 810 were randomly selected to ask approval from the provider for the trial; 574 were approved and sent a recruitment letter. Of 440 patients who were contacted, 280 subjects were randomized.


The Healthy Heart trial randomly assigned subjects to 1 telephone-based peer counseling session and office-based visits with trained mid-level providers over 6 time frames, or to a control condition of usual physician care. Practice providers nominated 20 patients to serve as peer coaches from lists of African Americans with well-controlled hypertension aged 50 to 75 years, because they were perceived to be “good communicators.” Of these, 11 completed training and 5 continued to the end of the study while 3 replacements were recruited and trained to assist with peer support. Training involved viewing and discussing illustrated slide shows created by the study team about CHD in the community and risks and barriers to control. Peer coaches were taught elements of motivational interviewing and practiced phone calls before being assigned patients. Peer coaches contacted intervention patients every other month for 6 months (minimum of 3 calls).

For practice-based counseling visits, we trained 3 African American staff members (eg, medical assistants) with the same slide shows used to train peers, and also trained them to use a personalized, computer-based, 4-year CHD risk calculator as a teaching tool. On alternate months from peer calls, patients made two 15- to 30-minute visits with trained practice staff to review personal CHD risk factors. All study subjects received culturally appropriate educational brochures and healthy recipes from the American Heart Association. Participants received $50 in gift certificates for participation ($20 at enrollment and $30 at end point visit). Peer coaches received $20 per completed phone call and followed a mean of 8 patients at once (other costs in Table 1). The protocol and procedures were reviewed and approved by the University of Pennsylvania Institutional Review Board.


Direct intervention costs were estimated from the perspective of the provider/ health system and measured in 2010 US dollars. Because the trial was based on outcomes monitored over 6 months, we did not apply any discounting. Specific resources used for the intervention included cost of training peer coaches, labor cost of peer coach telephone calls, cost of training office-based health educators, cost of clinic visits and laboratory tests, incentives for patients, cost of brochures, and cost of materials such as transportation, postage, and office supplies (Table 1). We also included costs for the overall administration of the trial, but not solely research-related costs. For the brochure control group, resources included the cost of clinic and laboratory visits and the cost of the brochures. Patients in the intervention group incurred all of these costs. Costs that were not relevant to the provider perspective, such as indirect costs for patients, were not considered.


We studied 2 measures of effectiveness for the withintrial stochastic cost-effectiveness analysis: predicted 6-month CHD risk avoided and 6-month improvements in SBP (per mm Hg). The 6-month CHD risk measure was derived from D’Agostino’s risk equations for primary events and secondary events in Framingham data (eg, myocardial infarction, angina), using original (rather than the calibrated) versions of these equations.5 Separate risk equations were used for men and women. Our primary CHD event end point combined predicted 6-month risk of primary and secondary CHD events for patients. All outcomes were based on an intention-to-treat approach. In the long-term costeffectiveness analysis, we studied 2 measures of effectiveness: years of life saved (YLS) and QALYs, both over a 10-year lifetime horizon.

Cost-Effectiveness Analysis

Two cost-effectiveness analyses were performed: a withintrial stochastic cost-effectiveness analysis that focused on cost-effectiveness during the 6-month trial period, and longterm cost-effectiveness based on a Markov model that modeled the longer-term benefits of BP reduction.6,7 For the within-trial stochastic cost-effectiveness analysis, we estimated 2 incremental cost-effectiveness ratios (ICERs): incremental cost per predicted CHD event avoided within 6 months, and incremental cost per mm Hg in SBP reduced. To characterize the uncertainty of the within-trial cost-effectiveness results, we used bootstrapping to estimate a 95% confidence ellipse around the ICER.8,9 The bootstrap method resampled the data 10,000 times with replacement, and computed the ICER for each replicate. From the bootstrap samples, we estimated the probability that one treatment was cost-effective compared with the other for a given willingness to pay (WTP). In addition, we computed the cost-effectiveness acceptability curve (CEAC) and plotted the probability that the behavioral health intervention was cost-effective over a reasonable range of levels of WTP.10

We performed a subgroup analysis for patients who were compliant with the intervention. We defined an effective “dose” as at least 2 peer coach calls and 1 practice visit. We then estimated the ICER for the intervention in this intervention subgroup relative to the control group. All stochastic cost-effectiveness analyses were performed using R statistical software (version 2.10.1,

Long Term Cost-Effectiveness

To estimate the long-term costs and benefits of BP reduction observed in the trial, data on costs and effectiveness from the clinical trial were entered into a Markov model of CHD risk in order to extrapolate trial results to a 10-year lifetime horizon. The Markov model was designed to study the impact of antihypertensive medications and was adapted to this setting. The model has a 10-year time horizon with yearly cycles. All costs begin in year 2010 US dollars and were discounted at a rate of 3%. Utility values for health states were drawn from Sullivan et al and Currie et al.13,14 As effectiveness measures, the model estimates YLS and QALYs. Additional details of the model are provided in Baker et al.11 Because the trial only lasted 6 months, it was necessary to make assumptions about how the intervention would be provided over the 10-year time horizon of the Markov model. We assumed that yearly reinforcements of the intervention would be required in order to sustain improvements.


The 280 intervention (N = 136) and control (N = 144) subjects were well balanced on demographics and clinical conditions (Table 2). Complete data to estimate CHD risk were available for 212 (94 intervention and 118 control)subjects and complete end point data were available for 247 (116 intervention and 131 control) subjects. Sixty-eight percent of intervention subjects (N = 79) were compliant with an effective “dose” intervention (ie, at least 2 peer coach calls and 1 practice visit) and included in the compliance subgroup analysis.

Baseline cost-effectiveness results (Table 3) show that the average cost over 6 months of the intervention was $435 for intervention subjects and $74 for control subjects. The intervention was successful in reducing both SBP and CHD risk. SBP fell by 7.2 mm Hg among intervention subjects, compared with only 0.77 mm Hg for control subjects (P = .0011). The average difference in CHD risk among intervention subjects fell by 0.046% but rose by 0.034% among control subjects (P = .07). The ICERs were $453,419 per predicted CHD event avoided over 6 months and $55 per mm Hg reduced in 6 months.

The uncertainty analysis for these ICERs (Figures 1A and 1B) shows a high probability that the intervention would rensult in a reduction in systolic blood pressure. The probability that the intervention is cost-effective is 25%, 50%, and 75% if the decision maker is willing to pay $45.20, $55.40, and $70.80, respectively, to reduce SBP by 1 mm Hg for at least 6 months (Figure 1B). For CHD risk, the CEAC suggests that the probability that the intervention is cost-effective for reducing CHD risk is 25%, 50%, and 75% if the decision maker is willing to pay $324,000, $449,000, and $674,000, respectively, to avoid 1 CHD event over 6 months (Figures 1C and 1D).

Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!